211 related articles for article (PubMed ID: 15815191)
1. Update in the management of patients with hormone-refractory prostate cancer.
Moore CN; George DJ
Curr Opin Urol; 2005 May; 15(3):157-62. PubMed ID: 15815191
[TBL] [Abstract][Full Text] [Related]
2. Future directions in the treatment of androgen-independent prostate cancer.
Petrylak DP
Urology; 2005 Jun; 65(6 Suppl):8-12. PubMed ID: 15939077
[TBL] [Abstract][Full Text] [Related]
3. [Hormonoresistant metastatic prostate cancer: analysis of two phase III clinical studies].
Ferrero JM
Bull Cancer; 2005 May; 92(5):425-7. PubMed ID: 15932803
[TBL] [Abstract][Full Text] [Related]
4. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.
Oudard S; Banu E; Beuzeboc P; Voog E; Dourthe LM; Hardy-Bessard AC; Linassier C; Scotté F; Banu A; Coscas Y; Guinet F; Poupon MF; Andrieu JM
J Clin Oncol; 2005 May; 23(15):3343-51. PubMed ID: 15738542
[TBL] [Abstract][Full Text] [Related]
5. Doxetaxel: new indication. Prostate cancer: a few more weeks.
Prescrire Int; 2006 Feb; 15(81):6-7. PubMed ID: 16548096
[TBL] [Abstract][Full Text] [Related]
6. Recent docetaxel studies establish a new standard of care in hormone refractory prostate cancer.
Van Poppel H
Can J Urol; 2005 Feb; 12 Suppl 1():81-5. PubMed ID: 15780173
[TBL] [Abstract][Full Text] [Related]
7. Docetaxel (Taxotere) in hormone-refractory prostate cancer.
Petrylak DP
Semin Oncol; 2000 Apr; 27(2 Suppl 3):24-9. PubMed ID: 10810935
[TBL] [Abstract][Full Text] [Related]
8. Docetaxel in hormone-refractory metastatic prostate cancer.
McKeage K; Keam SJ
Drugs; 2005; 65(16):2287-94; discussion 2295-7. PubMed ID: 16266195
[TBL] [Abstract][Full Text] [Related]
9. The current role of chemotherapy in metastatic hormone-refractory prostate cancer.
Petrylak DP
Urology; 2005 May; 65(5 Suppl):3-7; discussion 7-8. PubMed ID: 15885271
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy for hormone-refractory prostate cancer.
Shelley M; Harrison C; Coles B; Staffurth J; Wilt TJ; Mason MD
Cochrane Database Syst Rev; 2006 Oct; (4):CD005247. PubMed ID: 17054249
[TBL] [Abstract][Full Text] [Related]
11. The evolving role of chemotherapy in androgen-independent (hormone-refractory) prostate cancer.
Berry WR
Urology; 2005 Jun; 65(6 Suppl):2-7. PubMed ID: 15939076
[TBL] [Abstract][Full Text] [Related]
12. Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study.
Berthold DR; Pond GR; Roessner M; de Wit R; Eisenberger M; Tannock AI;
Clin Cancer Res; 2008 May; 14(9):2763-7. PubMed ID: 18451243
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy of prostate cancer: present and future.
Trump D; Lau YK
Curr Urol Rep; 2003 Jun; 4(3):229-32. PubMed ID: 12756087
[TBL] [Abstract][Full Text] [Related]
14. [Effective chemotherapy for hormone-refractory prostate cancer: docetaxel-prednisone].
Batman E; de Wit R
Ned Tijdschr Geneeskd; 2005 Oct; 149(44):2442-5. PubMed ID: 16285357
[TBL] [Abstract][Full Text] [Related]
15. [Promising new treatment options for metastatic androgen-independent prostate cancer].
Tan W
Actas Urol Esp; 2007 Jun; 31(6):680-5. PubMed ID: 17896565
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic options in androgen-independent prostate cancer: building on docetaxel.
Petrylak D
BJU Int; 2005 Dec; 96 Suppl 2():41-6. PubMed ID: 16359438
[TBL] [Abstract][Full Text] [Related]
17. A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer.
Collins R; Trowman R; Norman G; Light K; Birtle A; Fenwick E; Palmer S; Riemsma R
Br J Cancer; 2006 Aug; 95(4):457-62. PubMed ID: 16880788
[TBL] [Abstract][Full Text] [Related]
18. Which drug combination for hormone-refractory prostate cancer?
Doggrell SA
Expert Opin Pharmacother; 2005 Apr; 6(4):667-70. PubMed ID: 15934892
[TBL] [Abstract][Full Text] [Related]
19. Current chemotherapeutic approaches for androgen-independent prostate cancer.
Rumohr JA; Chang SS
Curr Opin Investig Drugs; 2006 Jun; 7(6):529-33. PubMed ID: 16784023
[TBL] [Abstract][Full Text] [Related]
20. Docetaxel in prostate cancer.
Small EJ
Anticancer Drugs; 2001 Feb; 12 Suppl 1():S17-20. PubMed ID: 11340899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]